[144] Mirum Pharmaceuticals, Inc. SEC Filing
Mirum Pharmaceuticals (MIRM) filed a Form 144 notifying a proposed sale of securities. The filing shows 17,000 common shares to be sold through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $1,309,715.70 and total shares outstanding listed as 50,237,647. The securities were acquired and are proposed to be sold on 09/08/2025 via a stock option exercise, with cash payment recorded. The filer reports no securities sold in the past three months for the account. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
Mirum Pharmaceuticals (MIRM) ha depositato un Modulo 144 comunicando l'intenzione di vendere titoli. La dichiarazione indica la vendita di 17.000 azioni ordinarie tramite Morgan Stanley Smith Barney su NASDAQ, con un valore di mercato complessivo di $1.309.715,70 e un totale di azioni in circolazione pari a 50.237.647. I titoli sono stati acquisiti e sono proposti in vendita il 09/08/2025 mediante un esercizio di opzione su azioni, con pagamento in contanti. Il dichiarante segnala nessuna vendita di titoli nei tre mesi precedenti per il conto. L'avviso include la dichiarazione richiesta che il venditore non 猫 a conoscenza di informazioni materiali avverse non divulgate.
Mirum Pharmaceuticals (MIRM) present贸 un Formulario 144 notificando una venta propuesta de valores. La presentaci贸n muestra 17.000 acciones ordinarias a venderse a trav茅s de Morgan Stanley Smith Barney en NASDAQ, con un valor de mercado agregado de $1,309,715.70 y un total de acciones en circulaci贸n de 50,237,647. Los valores fueron adquiridos y se proponen vender el 09/08/2025 mediante un ejercicio de opci贸n sobre acciones, con pago en efectivo. El declarante informa no haber vendido valores en los 煤ltimos tres meses para la cuenta. El aviso incluye la representaci贸n requerida de que el vendedor no conoce informaci贸n adversa material no divulgada.
Mirum Pharmaceuticals(MIRM)臧� 歃濌秾 毵り皝 鞓堨爼 靷嫟鞚� 韱奠頃橂姅 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 靹滊鞐愲姅 Morgan Stanley Smith Barney毳� 韱淀暣 NASDAQ鞐愳劀 毵り皝霅� 17,000 氤错喌欤�臧� 旮办灛霅橃柎 鞛堨溂氅�, 齑� 鞁滌灔 臧�旃� $1,309,715.70 氚� 氚滍枆 欤检嫕 齑濎垬 50,237,647臧� 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 歃濌秾鞚� 2025雲� 09鞗� 08鞚�鞐� 鞀ろ啞鞓奠厴 頄夓偓搿� 旆摑霅橃棃瓿� 毵り皝鞚� 鞝滌晥霅橃棃鞙茧┌, 顺勱笀鞙茧 雽�旮堨澊 瓴办牅霅橃棃鞀惦媹雼�. 氤搓碃鞛愲姅 頃措嫻 瓿勳爼鞐� 雽�頃� 瓿缄卑 3臧滌洈臧� 毵り皝頃� 歃濌秾鞚� 鞐嗢棃雼�瓿� 氤搓碃頃╇媹雼�. 韱奠靹滌棎電� 韺愲Г鞛愱皜 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岇 氇豁暅雼る姅 頃勳垬 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Mirum Pharmaceuticals (MIRM) a d茅pos茅 un formulaire 144 annon莽ant une cession propos茅e de titres. Le dossier indique la vente de 17 000 actions ordinaires via Morgan Stanley Smith Barney sur le NASDAQ, pour une valeur de march茅 totale de 1 309 715,70 $ et un total d'actions en circulation de 50 237 647. Les titres ont 茅t茅 acquis et sont propos茅s 脿 la vente le 09/08/2025 par exercice d'option sur actions, le paiement ayant 茅t茅 effectu茅 en 别蝉辫猫肠别蝉. Le d茅posant signale aucune vente de titres au cours des trois derniers mois pour le compte. L'avis inclut la d茅claration requise selon laquelle le vendeur n'est pas au courant d'informations d茅favorables importantes non divulgu茅es.
Mirum Pharmaceuticals (MIRM) reichte ein Formular 144 ein, das einen geplanten Verkauf von Wertpapieren ank眉ndigt. Die Einreichung weist 17.000 Stammaktien aus, die 眉ber Morgan Stanley Smith Barney an der NASDAQ verkauft werden sollen, mit einem gesamten Marktwert von $1.309.715,70 und insgesamt 50.237.647 ausstehenden Aktien. Die Wertpapiere wurden am 09.08.2025 durch Aus眉bung einer Aktienoption erworben und sollen verkauft werden; die Zahlung erfolgte in Barkasse. Der Melder gibt an, dass in den vergangenen drei Monaten keine Wertpapiere f眉r das Konto verkauft wurden. Die Mitteilung enth盲lt die erforderliche Zusicherung, dass dem Verk盲ufer keine nicht offen gelegten, wesentlichen nachteiligen Informationen bekannt sind.
- Full transaction details provided: number of shares (17,000), aggregate value ($1,309,715.70), broker (Morgan Stanley Smith Barney) and exchange (NASDAQ)
- Acquisition and payment method disclosed: acquired by stock option exercise on 09/08/2025 with cash payment
- No sales in prior three months reported for the account, aiding Rule 144 aggregation clarity
- Seller attestation included that they do not know undisclosed material adverse information
- None.
Insights
TL;DR: Routine Rule 144 notice for an insiders' sale following option exercise; disclosure provides size and timing but no new company fundamentals.
The filing documents a proposed sale of 17,000 shares valued at $1,309,715.70, executed through Morgan Stanley Smith Barney and to be traded on NASDAQ. The shares were acquired by stock option exercise on the same date as the proposed sale, with cash payment to the issuer. The filer indicates no sales in the prior three months, which is relevant for Rule 144 aggregation and volume calculations. This is a procedural disclosure rather than a fundamental change to the issuer's business or financial condition.
TL;DR: Compliance-focused filing showing the seller's attestation and transaction mechanics; typical governance transparency.
The Form 144 includes the seller's representation that they are unaware of undisclosed material adverse information and records transaction mechanics: acquisition by option exercise and cash payment, broker identity, and planned sale date. It satisfies Rule 144 notice requirements and provides investors with clear information on insider selling mechanics without introducing new governance issues or disclosures.
Mirum Pharmaceuticals (MIRM) ha depositato un Modulo 144 comunicando l'intenzione di vendere titoli. La dichiarazione indica la vendita di 17.000 azioni ordinarie tramite Morgan Stanley Smith Barney su NASDAQ, con un valore di mercato complessivo di $1.309.715,70 e un totale di azioni in circolazione pari a 50.237.647. I titoli sono stati acquisiti e sono proposti in vendita il 09/08/2025 mediante un esercizio di opzione su azioni, con pagamento in contanti. Il dichiarante segnala nessuna vendita di titoli nei tre mesi precedenti per il conto. L'avviso include la dichiarazione richiesta che il venditore non 猫 a conoscenza di informazioni materiali avverse non divulgate.
Mirum Pharmaceuticals (MIRM) present贸 un Formulario 144 notificando una venta propuesta de valores. La presentaci贸n muestra 17.000 acciones ordinarias a venderse a trav茅s de Morgan Stanley Smith Barney en NASDAQ, con un valor de mercado agregado de $1,309,715.70 y un total de acciones en circulaci贸n de 50,237,647. Los valores fueron adquiridos y se proponen vender el 09/08/2025 mediante un ejercicio de opci贸n sobre acciones, con pago en efectivo. El declarante informa no haber vendido valores en los 煤ltimos tres meses para la cuenta. El aviso incluye la representaci贸n requerida de que el vendedor no conoce informaci贸n adversa material no divulgada.
Mirum Pharmaceuticals(MIRM)臧� 歃濌秾 毵り皝 鞓堨爼 靷嫟鞚� 韱奠頃橂姅 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 靹滊鞐愲姅 Morgan Stanley Smith Barney毳� 韱淀暣 NASDAQ鞐愳劀 毵り皝霅� 17,000 氤错喌欤�臧� 旮办灛霅橃柎 鞛堨溂氅�, 齑� 鞁滌灔 臧�旃� $1,309,715.70 氚� 氚滍枆 欤检嫕 齑濎垬 50,237,647臧� 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 歃濌秾鞚� 2025雲� 09鞗� 08鞚�鞐� 鞀ろ啞鞓奠厴 頄夓偓搿� 旆摑霅橃棃瓿� 毵り皝鞚� 鞝滌晥霅橃棃鞙茧┌, 顺勱笀鞙茧 雽�旮堨澊 瓴办牅霅橃棃鞀惦媹雼�. 氤搓碃鞛愲姅 頃措嫻 瓿勳爼鞐� 雽�頃� 瓿缄卑 3臧滌洈臧� 毵り皝頃� 歃濌秾鞚� 鞐嗢棃雼�瓿� 氤搓碃頃╇媹雼�. 韱奠靹滌棎電� 韺愲Г鞛愱皜 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岇 氇豁暅雼る姅 頃勳垬 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Mirum Pharmaceuticals (MIRM) a d茅pos茅 un formulaire 144 annon莽ant une cession propos茅e de titres. Le dossier indique la vente de 17 000 actions ordinaires via Morgan Stanley Smith Barney sur le NASDAQ, pour une valeur de march茅 totale de 1 309 715,70 $ et un total d'actions en circulation de 50 237 647. Les titres ont 茅t茅 acquis et sont propos茅s 脿 la vente le 09/08/2025 par exercice d'option sur actions, le paiement ayant 茅t茅 effectu茅 en 别蝉辫猫肠别蝉. Le d茅posant signale aucune vente de titres au cours des trois derniers mois pour le compte. L'avis inclut la d茅claration requise selon laquelle le vendeur n'est pas au courant d'informations d茅favorables importantes non divulgu茅es.
Mirum Pharmaceuticals (MIRM) reichte ein Formular 144 ein, das einen geplanten Verkauf von Wertpapieren ank眉ndigt. Die Einreichung weist 17.000 Stammaktien aus, die 眉ber Morgan Stanley Smith Barney an der NASDAQ verkauft werden sollen, mit einem gesamten Marktwert von $1.309.715,70 und insgesamt 50.237.647 ausstehenden Aktien. Die Wertpapiere wurden am 09.08.2025 durch Aus眉bung einer Aktienoption erworben und sollen verkauft werden; die Zahlung erfolgte in Barkasse. Der Melder gibt an, dass in den vergangenen drei Monaten keine Wertpapiere f眉r das Konto verkauft wurden. Die Mitteilung enth盲lt die erforderliche Zusicherung, dass dem Verk盲ufer keine nicht offen gelegten, wesentlichen nachteiligen Informationen bekannt sind.
FAQ
What does Mirum Pharmaceuticals' (MIRM) Form 144 disclose?
How were the shares acquired for the MIRM Form 144 filing?
Does the Form 144 report any sales by this person in the past three months?
What is the aggregate market value and outstanding shares reported?
Which broker and exchange are named in the Form 144?
